Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)

(2020) Matteo Bassetti et al.   Open Forum Infectious Diseases

Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline

(2020) Sara E Boyd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

(2020) Jorge Arca-Suárez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Primer on AmpC Beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-Resistant World

(2019) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

Comparison of ceftazidime-avibactam and Ceftolozane-Tazobactam in vitro activities when tested against gram-negative Bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)

(2019) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa

(2019) José-Manuel Ortiz de la Rosa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa

(2019) Jason M Pogue et al.   CLINICAL INFECTIOUS DISEASES

The Global Ascendency of OXA-48-Type Carbapenemases

(2019) Johann D. D. Pitout et al.   CLINICAL MICROBIOLOGY REVIEWS

In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)

(2019) James A. Karlowsky et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program

(2019) Dee Shortridge et al.   Journal of Global Antimicrobial Resistance

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from United States Hospitals and Comparative Activity of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes

(2018) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli

(2018) Suzannah M. Schmidt-Malan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Imipenem-Relebactam against Gram-Negative Bacilli from Global ICU and Non-ICU Wards — SMART 2015-2016

(2018) Sibylle H. Lob et al.   Journal of Global Antimicrobial Resistance

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

(2017) Pablo A Fraile-Ribot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials

(2016) Myra W. Popejoy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The global epidemiology of carbapenemase-producing Enterobacteriaceae

(2016) David van Duin et al.   Virulence

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2015) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals

(2014) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)

(2014) David J. Farrell et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

Current Challenges in Antimicrobial Chemotherapy

(2010) Carine Bebrone et al.   DRUGS

Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa

(2009) J.-M. Rodriguez-Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AmpC  -Lactamases

(2009) G. A. Jacoby   CLINICAL MICROBIOLOGY REVIEWS